Raloxifene Has No Efficacy in Reducing the High Bone Turnover and the Risk of Spontaneous Vertebral Fractures after Denosumab Discontinuation

At denosumab discontinuation, an antiresorptive agent is prescribed to reduce the high bone turnover, the rapid bone loss, and the risk of spontaneous vertebral fractures. We report the case of a woman treated with aromatase inhibitors and denosumab for 5 years. Raloxifene was then prescribed to pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez-Rodriguez, Elena, Stoll, Delphine, Lamy, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166370/
https://www.ncbi.nlm.nih.gov/pubmed/30310704
http://dx.doi.org/10.1155/2018/5432751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166370/
https://www.ncbi.nlm.nih.gov/pubmed/30310704
http://dx.doi.org/10.1155/2018/5432751

Ejemplares similares